Equity Research Biotechnology

Should You Buy ZyVersa Therapeutics, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, ZyVersa Therapeutics, Inc. (ZVSA) registers a weak Quality of Company score of 3.5/10. At the current price of $0.10, our 13-model framework evaluates whether the stock's discount is sufficient to compensate for high fundamental risks.

The short answer: 0 of 0 CirclFi valuation models project upside for ZyVersa Therapeutics, Inc. (ZVSA) at $0.10 — the models are evenly split, with a Quality Score of 3.5/10 and Value-Trap risk of 63/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 3.5/10 — Weak — below-average fundamentals
  • Value Trap Risk: 63/100 — High danger — likely trap
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

3.5 /10

Weak — below-average fundamentals

Value Trap Risk

63 /100
High danger

High danger — likely trap

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for ZyVersa Therapeutics, Inc. (ZVSA) in 2026?

What Is the Bull Case vs the Bear Case for ZyVersa Therapeutics, Inc. (ZVSA)?

Bull case versus bear case for ZyVersa Therapeutics, Inc. (ZVSA) at $0.10, derived from 0 active CirclFi valuation models on 2026-08-27.
Bull case Bear case
No active model projects meaningful upside for ZVSA at $0.10. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for ZVSA. The Value Trap score of 63/100 still argues for some caution.

How Does ZVSA Compare to Its Biotechnology Peers?

XCUR Exicure, Inc.
3.5
KARD Kardigan, Inc.
3.5
HURA TuHURA Biosciences,
3.5
ADTX Aditxt, Inc.
3.4
PCSA Processa Pharmaceuti
3.5
KLRA Kailera Therapeutics
3.4
STRO Sutro Biopharma, Inc
6.3
CRBU Caribou Biosciences,
5.2

Valuation data pages: XCUR · KARD · HURA · ADTX · PCSA · KLRA · STRO · CRBU · SNTI · EXEL · INCY

See full Biotechnology rankings →

Which Other Stocks Score Like ZVSA on Quality?

Closest companies to ZVSA’s Quality of Company score of 3.5/10, across all industries.

Which Biotechnology Screens Does ZVSA Appear In?

Why Do CirclFi’s 0 Models Disagree on ZVSA?

What Are the Biggest Risks of Buying ZVSA Stock?

Weak Fundamentals

QOC 3.5/10 signals below-average quality.

Value Trap Warning

VT score 63/100 — apparent discount may mask decay.

Macro/Sector Risk

Biotechnology headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ZVSA Data Page →

So Is ZyVersa Therapeutics, Inc. (ZVSA) Worth Buying in 2026?

ZyVersa Therapeutics, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. ZyVersa Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ZVSA Stock?

Should I buy ZVSA stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for ZVSA at $0.10. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in ZyVersa Therapeutics, Inc.?

Key risks include: an elevated Value Trap score of 63/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 3.5/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.

How does ZVSA compare to its competitors?

Among Biotechnology peers, ZVSA holds a Quality Score of 3.5/10. Comparable companies include XCUR (QOC 3.5), KARD (QOC 3.5), HURA (QOC 3.5). The relative ranking helps investors identify whether ZVSA offers better fundamental quality than alternatives in the same sector.

Is ZVSA a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ZVSA's Quality Score of 3.5/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy ZVSA at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ZVSA.

View ZVSA Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →